Medical/Pharmaceuticals
OncoC4 Announces Oral Presentation of a Late-Breaking Abstract on Cesalatamig at the 41st Annual Meeting of SITC
— Global Phase 1/2 Study Data in PD-(L)1–Resistant/Refractory NSCLC to Be Presented on November 7, 2026 — — Clinical Oral Abstract Session 2 Begins at 1:45 PM MST — ROCKVILLE, Md., Oct. 29, 2026 /PRNewswire/ -- OncoC4 Inc., a late clinical-stage biopharmaceutical company developing novel medicin...
2026-10-29 21:30
5981
Yuyu Pharma Explores Animal Health as a New Pathway for Human Drug Innovation
SEOUL, South Korea, Oct. 29, 2026 /PRNewswire/ -- Yuyu Pharma (KRX: 000220) CEO Robert Wonsang Yu shared the company's vision for connecting human and animal health at BIOPLUS-INTERPHEX KOREA 2026 (BIX 2026), highlighting how pharmaceutical research and development can create new opportunities ac...
2026-10-29 21:00
3620
United Imaging Healthcare Reports 19.43% Revenue Growth in First Nine Months of 2026, with Cumulative R&D Investment Exceeding RMB 10 Billion Since 2022
SHANGHAI, Oct. 29, 2026 /PRNewswire/ -- United Imaging Healthcare (688271.SH), a global innovator in advanced medical imaging technologies and intelligent healthcare solutions, reported revenue of RMB 10.58 billion for the first nine months of 2026, up 19.43% year-on-year. Sustained investment in...
2026-10-29 15:32
4139
SGH's AI tool wins international award for improving antibiotic use
SINGAPORE, Oct. 29, 2026 /PRNewswire/ -- Singapore General Hospital (SGH) has won the Silver Award in the Dr Prathap C Reddy Excellence Award for Clinical Quality and Patient Safety at the International Hospital Federation (IHF) Awards 2026, for its Augmented Intelligence in Infectious Diseases (...
2026-10-29 14:00
4009
Total Investment of Approx. USD 6.8 Million in Product Development for Malaria, NTDs and Other Emerging & Re-emerging Infectious Diseases Such as Ebola Disease
TOKYO, Oct. 29, 2026 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.06 billion (USD 6.8 million1) in nine R&D projects for the development of drugs, vaccines and diagnostics for malaria, neglected tropical diseases (NT...
2026-10-29 10:00
3458
Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted HbA1c Reduction of 1.7% at 12 Weeks from Its U.S. Phase II Study in Participants with Diabetes
- ASC30 reduced HbA1c by a placebo-adjusted 1.7%, 1.6% and 1.7% from baseline for 40 mg, 60 mg and 80 mg, respectively, at 12 weeks, the primary endpoint. - ASC30 achieved placebo-adjusted weight reduction of 4.4%, 3.8% and 4.0% from baseline for 40 mg, 60 mg and 80 mg, respectively and no platea...
2026-10-29 07:40
3900
IFPA: World Psoriasis Day 2026, Young people speak up against stigma and discrimination
STOCKHOLM, Oct. 28, 2026 /PRNewswire/ -- More than 100 million people worldwide live with psoriasis and psoriatic arthritis, and one in three develop first symptoms before age of 20. This World Psoriasis Day, October 29, IFPA (the International Federation of Psoriasis Associations) is launching a...
2026-10-28 19:30
2180
IMDA and NUH Partner in First Open Innovation Platform Collaboration in Public Healthcare
Partnership accelerates healthcare innovation by connecting real-world hospital needs with technology expertise SINGAPORE, Oct. 28, 2026 /PRNewswire/ -- The Infocomm Media Development Authority (IMDA) and the National University Hospital (NUH), through its Kent Ridge Office of Innovation (KROI),...
2026-10-28 17:04
2526
Ozelle to Spotlight Scalable AI-Assisted Hematology with O-Cyte 1 at MEDICA 2026
O-Cyte 1 combines CBC testing and reviewable cell images with expandable throughput and service-ready design. DÜSSELDORF, Germany, Oct. 28, 2026 /PRNewswire/ -- As AI-assisted morphology becomes more integrated into routine hematology, laboratories need more than automated cell classification. C...
2026-10-28 16:15
2566
CELSET Launches SOLTOX, a Korean Botulinum Toxin Type A Brand, for International Markets
SEOUL, South Korea, Oct. 28, 2026 /PRNewswire/ -- CELSET INC., a Korean
biotechnology company specializing in medical aesthetics, has launched SOLTOX,
its botulinum toxin type A brand, introducing a Korean botulinum toxin brand to
the international medical aesthetics industry.
2026-10-28 16:00
2874
Jiahui Launches International Cell Therapy Center to Expand Global Access to CAR-T Treatment
SHANGHAI, Oct. 28, 2026 /PRNewswire/ -- Jiahui International Hospital launched Jiahui International Cell Therapy Center, building on landmark CAR-T cases and multidisciplinary expertise to serve patients from China and abroad. The center was unveiled at the inaugural Jiahui International Cell The...
2026-10-28 14:41
2415
The Jumbophage Cocktail_Fighting Superbugs and Shrimp Disease
BANGKOK, Oct. 28, 2026 /PRNewswire/ -- What if a weapon against some of the world's most stubborn bacteria were hiding in the soil beneath our feet? Could these microscopic hunters help us confront antibiotic-resistant "superbugs" and bacterial diseases devastating shrimp? The answer may lie in u...
2026-10-28 14:24
3500
Docquity Extends Asian Healthcare Intelligence to the Middle East Through Strategic Partnership with Growth Partner Holding
Saudi Arabia launch opens the region, with expansion planned into Egypt, Turkey, Jordan and Iraq; Ask Dx is the core platform RIYADH, Saudi Arabia and SINGAPORE, Oct. 28, 2026 /PRNewswire/ -- Docquity, the clinical AI platform for more than 500,000 verified doctors across Asia, today announced a...
2026-10-28 13:40
3878
From China to the Global Stage: Hengrui Showcases Innovative Research at ESMO Congress 2026, Exploring New Approaches to Oncology Treatment
Record 64 Research Presentations Highlight Hengrui's Oncology R&D Strength and Growing International Reach MADRID and SHANGHAI, Oct. 27, 2026 /PRNewswire/ -- The European Society for Medical Oncology (ESMO) Congress 2026 recently concluded in Madrid. As a leading innovator in China's pharmaceuti...
2026-10-28 11:32
3881
Lynk Pharmaceuticals Reports Positive Long-Term Phase III Results for Zemprocitinib in bDMARDs-Inadequate Responders with Moderate-to-Severe Rheumatoid Arthritis
HANGZHOU, China, SHANGHAI and BOSTON, Oct. 28, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced positive long-term results from its pivotal Phase III clin...
2026-10-28 08:00
4348
Fosun Health Makes Historic Debut at Canton Fair, Foshan Fosun Chancheng Hospital Showcases International Healthcare Services
GUANGZHOU, China, Oct. 28, 2026 /PRNewswire/ -- Fosun Health has become the first cross-border international healthcare group to exhibit at the Canton Fair in its 70-year history, debuting at the event's inaugural International Healthcare Zone alongside four Greater Bay Area (GBA) hospitals, incl...
2026-10-28 08:00
5151
Registrational Phase III CLARIFY trial: Target number of participants achieved
SYDNEY, Oct. 27, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the registration...
2026-10-27 21:02
3123
How to Care for Caregivers? NCCN Debuts Essential Guide for Supporting Loved Ones with Cancer
New, free book offers simple but empowering information on how to care for people with cancer while also caring for yourself. PLYMOUTH MEETING, Pa., Oct. 27, 2026 /PRNewswire/ -- Today, the National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers in the United States ...
2026-10-27 20:07
2912
New Indication Application for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Accepted for Review by NMPA
* This is the seventh indication application for sacituzumab tirumotecan (sac-TMT) and the second application for the ADC plus IO combination regimen of sac-TMT plus pembrolizumab accepted for review. * The Phase III OptiTROP-Lung06 study supporting this application showed that sac-TMT plus p...
2026-10-27 19:10
3876
Hengrui Pharma Reports Steady Growth in the First Nine Months of 2026
SHANGHAI, Oct. 27, 2026 /PRNewswire/ -- Hengrui Pharma ("Hengrui" or "the Company") today announced its financial results for the first nine months of 2026. During this period, Hengrui reported revenue of RMB24.41 billion, representing a year-over-year increase of 5.26%. Product sales revenue was...
2026-10-27 18:04
3876
Week's Top Stories
Most Reposted
TD Brings its Global Asset Management Businesses Under One Name
[Picked up by 1168 media titles]
2026-11-02 20:00OceanaGold Reports Third Quarter 2026 Results
[Picked up by 1129 media titles]
2026-11-05 06:52Overstory Launches Integrated AI Platform to Deliver First Living Model of Grid Risk
[Picked up by 1082 media titles]
2026-11-03 22:00Fintech OPay Raises $304 Million Ahead of NYSE Debut: NYSE Content Update
[Picked up by 1079 media titles]
2026-10-30 22:34
H.E. Ahmed Al-Khateeb, Saudi Minister of Tourism, Inaugurates Saudi Land at WTM London 2026, Reinforcing Saudi's Commitment to Global Travel Trade
[Picked up by 1067 media titles]
2026-11-04 07:31
Most Read
1B views since June: Coda and TikTok Gaming turn content into commerce
2026-11-02 09:35
62161
Airbrush Upgrades AI Image Enhancer With 16K Output and Batch Processing for Up to 50 Images
2026-11-03 02:00
57935
iQIYI Launches China's First AI Film Studio in Shanghai, with Inaugural Title "Cop in Trouble" in Production
2026-11-02 09:52
55250
Korean Derma Skincare Brand MDP+ Launches at Nordstrom
2026-11-03 00:30
24715
